Bone Turnover Markers in Osteogenesis Imperfecta and Effect of Bisphosphonate Treatment: First Egyptian Study

Nazim W S; Temtamy S A; Sayed O; Otaify G A; Ibrahim M M; Aglan M S; Gouda AS

Nazim W S Biochemical Genetics Department, Human Genetics and Genome Research Division, Center of Excellence of Human Genetics, National Research Centre
Temtamy S A Clinical Genetics Department, Human Genetics and Genome Research Division, Center of Excellence of Human Genetics, National Research Centre
Sayed O Biochemistry Department, Faculty of Pharmacy, Azhar University (Girls)
Otaify G A Clinical Genetics Department, Human Genetics and Genome Research Division, Center of Excellence of Human Genetics, National Research Centre
Ibrahim M M Biochemical Genetics Department, Human Genetics and Genome Research Division, Center of Excellence of Human Genetics, National Research Centre
Aglan M S Clinical Genetics Department, Human Genetics and Genome Research Division, Center of Excellence of Human Genetics, National Research Centre
Gouda AS Biochemical Genetics Department, Human Genetics and Genome Research Division, Center of Excellence of Human Genetics, National Research Centre

Keywords: osteogenesis imperfecta, bone formation, bone resorption, bone turnover markers, bisphosphonates, type I collagen.

Abstract

Purpose: This report studies the changes in bone turnover markers in Egyptian OI patients and the effect of bisphosphonate treatment on these biomarkers. Methods: Twenty-six OI patients, and 30 controls were included. Age range of patients was 6.22 ± 3.72 years, while age range of controls was 11.1 ± 3.36 years. Serum calcium, phosphorus, parathormone, 25(OH) vitamin D, 1,25 (OH)2 vitamin D in addition to bone formation and degradation markers including: osteocalcin and procollagen type I N propeptide and urinary helical peptide, N-telopeptide, isomerized and non-isomerized C-telopeptide, pyridinoline and deoxypyridinoline were measured at baseline, 6 months and 12 months of bisphosphonate treatment. Results: All biochemical measurements except parathormone showed no significant difference. Bone formation markers and type I collagen degradation markers showed significant differences. Conclusions: Biochemical measurement of serum calcium is recommended in patients receiving bisphosohonates. Bone formation markers and markers of type I collagen degradation are valuable for monitoring the effect of bisphosphonate treatment in OI patients.